Clinical Trial Update: Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 study comparing once-daily vs conventional dosing of Asacol (mesalamine) for maintaining quiescent ulcerative colitis; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Asacol (mesalamine)

Snippet

Sponsor: University of Chicago | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED